Compare CAN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAN | LXRX |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 541.5M |
| IPO Year | 2019 | 2000 |
| Metric | CAN | LXRX |
|---|---|---|
| Price | $0.80 | $1.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $3.56 | $3.23 |
| AVG Volume (30 Days) | ★ 27.3M | 1.5M |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,228,000.00 | $70,864,000.00 |
| Revenue This Year | $91.42 | $56.61 |
| Revenue Next Year | $47.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 83.87 | ★ 1255.21 |
| 52 Week Low | $0.53 | $0.28 |
| 52 Week High | $3.27 | $1.66 |
| Indicator | CAN | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 39.77 |
| Support Level | $0.91 | $1.29 |
| Resistance Level | $0.93 | $1.48 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 6.78 | 8.70 |
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.